201 related articles for article (PubMed ID: 11521799)
1. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.
Waldherr C; Pless M; Maecke HR; Haldemann A; Mueller-Brand J
Ann Oncol; 2001 Jul; 12(7):941-5. PubMed ID: 11521799
[TBL] [Abstract][Full Text] [Related]
2. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using.
Waldherr C; Schumacher T; Pless M; Crazzolara A; Maecke HR; Nitzsche EU; Haldemann A; Mueller-Brand J
Nucl Med Commun; 2001 Jun; 22(6):673-8. PubMed ID: 11403179
[TBL] [Abstract][Full Text] [Related]
3. Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue.
Waldherr C; Haldemann A; Maecke HR; Crazzolara A; Mueller-Brand J
Clin Oncol (R Coll Radiol); 2000; 12(2):121-3. PubMed ID: 10853753
[TBL] [Abstract][Full Text] [Related]
4. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients.
Paganelli G; Zoboli S; Cremonesi M; Mäcke HR; Chinol M
Cancer Biother Radiopharm; 1999 Dec; 14(6):477-83. PubMed ID: 10850334
[TBL] [Abstract][Full Text] [Related]
5. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Waldherr C; Pless M; Maecke HR; Schumacher T; Crazzolara A; Nitzsche EU; Haldemann A; Mueller-Brand J
J Nucl Med; 2002 May; 43(5):610-6. PubMed ID: 11994522
[TBL] [Abstract][Full Text] [Related]
6. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
[TBL] [Abstract][Full Text] [Related]
7. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide.
Paganelli G; Zoboli S; Cremonesi M; Bodei L; Ferrari M; Grana C; Bartolomei M; Orsi F; De Cicco C; Mäcke HR; Chinol M; de Braud F
Eur J Nucl Med; 2001 Apr; 28(4):426-34. PubMed ID: 11357492
[TBL] [Abstract][Full Text] [Related]
8. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
Bodei L; Cremonesi M; Grana C; Rocca P; Bartolomei M; Chinol M; Paganelli G
Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):1038-46. PubMed ID: 15150675
[TBL] [Abstract][Full Text] [Related]
9. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.
Forrer F; Waldherr C; Maecke HR; Mueller-Brand J
Anticancer Res; 2006; 26(1B):703-7. PubMed ID: 16739341
[TBL] [Abstract][Full Text] [Related]
10. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.
Merlo A; Hausmann O; Wasner M; Steiner P; Otte A; Jermann E; Freitag P; Reubi JC; Müller-Brand J; Gratzl O; Mäcke HR
Clin Cancer Res; 1999 May; 5(5):1025-33. PubMed ID: 10353735
[TBL] [Abstract][Full Text] [Related]
11. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.
Baum RP; Kluge AW; Kulkarni H; Schorr-Neufing U; Niepsch K; Bitterlich N; van Echteld CJ
Theranostics; 2016; 6(4):501-10. PubMed ID: 26941843
[TBL] [Abstract][Full Text] [Related]
12. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
Bodei L; Handkiewicz-Junak D; Grana C; Mazzetta C; Rocca P; Bartolomei M; Lopera Sierra M; Cremonesi M; Chinol M; Mäcke HR; Paganelli G
Cancer Biother Radiopharm; 2004 Feb; 19(1):65-71. PubMed ID: 15068613
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
14. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Bushnell D; Menda Y; O'Dorisio T; Madsen M; Miller S; Carlisle T; Squires S; Kahn D; Walkner W; Connolly M; O'Dorisio S; Karwal M; Ponto J; Bouterfa H
Cancer Biother Radiopharm; 2004 Feb; 19(1):35-41. PubMed ID: 15068609
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of radiolabelled somatostatin analogues (
Medina-Ornelas SS; García-Pérez FO
Rev Esp Med Nucl Imagen Mol; 2017; 36(3):166-174. PubMed ID: 27890514
[TBL] [Abstract][Full Text] [Related]
16. End-stage renal disease after treatment with 90Y-DOTATOC.
Cybulla M; Weiner SM; Otte A
Eur J Nucl Med; 2001 Oct; 28(10):1552-4. PubMed ID: 11685499
[TBL] [Abstract][Full Text] [Related]
17. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies.
Paganelli G; Bodei L; Handkiewicz Junak D; Rocca P; Papi S; Lopera Sierra M; Gatti M; Chinol M; Bartolomei M; Fiorenza M; Grana C
Biopolymers; 2002; 66(6):393-8. PubMed ID: 12658726
[TBL] [Abstract][Full Text] [Related]
18. Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide.
Savelli G; Bertagna F; Franco F; Dognini L; Bosio G; Migliorati E; Rodella C; Biasiotto G; Bettinsoli G; Minari C; Zaniboni A; Ferrari C; Tomassetti P; Ferrari V; Giubbini R
Cancer; 2012 Jun; 118(11):2915-24. PubMed ID: 22020784
[TBL] [Abstract][Full Text] [Related]
19. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.
de Jong M; Bakker WH; Krenning EP; Breeman WA; van der Pluijm ME; Bernard BF; Visser TJ; Jermann E; Béhé M; Powell P; Mäcke HR
Eur J Nucl Med; 1997 Apr; 24(4):368-71. PubMed ID: 9096086
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.
Kwekkeboom DJ; Bakker WH; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Feelders RA; van Eijck CH; de Jong M; Srinivasan A; Erion JL; Krenning EP
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):417-22. PubMed ID: 12634971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
